ACRO Forecasts Radiologist Surplus

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 1
Volume 5
Issue 1

OAK BROOK, Ill--Young physicians seeking careers in radiation on-cology may have severely limited employment opportunities in the foreseeable future, according to the American College of Radiation Oncology (ACRO). The College forecasts that up to 1,000 radiation oncologists will be either underemployed or unemployed shortly after the year 2000.

OAK BROOK, Ill--Young physicians seeking careers in radiationon-cology may have severely limited employment opportunities inthe foreseeable future, according to the American College of RadiationOncology (ACRO). The College forecasts that up to 1,000 radiationoncologists will be either underemployed or unemployed shortlyafter the year 2000.

The College's Personnel Needs Assessment Committee found thatapproximately 800 new radiation oncologists will enter the jobmarket in the next 5 years while fewer than 200 existing radiationoncologists will leave the workforce during the same period.

Quality of Training Affected

The Committee anticipates that the annual average caseload isexpected to remain between 210 and 216 patients through the year2004. A surplus of radiation oncologists may decrease patientcaseload at large medical centers and limit the number of patientsavailable for resident training, thereby adversely affecting thequality of training available to radiation oncology residents.

"The word needs to get out," said ACRO president WilliamD. Bloomer. "Unlike medical subspecialists who can fall backon general internal medicine if their specialty practice falters,radiation oncologists have no fall-back position without majorre-training."

Recent Videos
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
4 experts in this video
Related Content